Clinical trial
DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer
NCT00024414 · Theradex, Industry · Unknown status
Key facts
| NCT number | NCT00024414 |
|---|---|
| Title | DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer |
| Official title | Phase II Open-Label Study of Taxoprexin (DHA-Paclitaxel) Injection by 2-Hour Intravenous Infusion in Patients With Metastatic Hormone-Refractory Prostate Cancer |
| Lead sponsor | Theradex, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | DHA-paclitaxel |
| Start date | Apr 1, 2001 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 24, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: